Clinical Trial

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

Name: A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 — clinical trial record (NCT06668064)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: wAMD

Active, Not Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Protocol Amendment History 1 change

notable Trial sites reduced: 79 -> 76 locations 2026-05-05

Trial Details

NCT Number	NCT06668064
Lead Sponsor	EyePoint Pharmaceuticals, Inc.
Conditions	Wet Age Related Macular Degeneration, wAMD
Enrollment	400 participants
Start Date	2024-10-22
Primary Completion	2026-08 (estimated)
Study Completion	2027-08 (estimated)
Updated on ClinicalTrials.gov	2026-08-04